Project

Back to overview

The Swiss Hepatitis C Cohort Study

English title The Swiss Hepatitis C Cohort Study
Applicant Negro Francesco
Number 177521
Funding scheme Cohort Studies Large
Research institution Service de Gastroentérologie Hopitaux Universitaires de Genève
Institution of higher education University of Geneva - GE
Main discipline Internal Medicine
Start/End 01.01.2018 - 31.12.2019
Approved amount 1'918'050.00
Show all

Keywords (4)

Chronic hepatitis; Cirrhosis; Hepatitis C; Hepatocellular carcinoma

Lay Summary (French)

Lead
L'Etude Suisse de Cohorte Hépatite C permet de mener des études autour des questions scientifiques encore ouvertes dans le domaine de l'hépatite C
Lay summary
Le virus de l'hépatite C est un agent infectieux à diffusion globale, et une des causes les plus importantes de la mortalité liée au foie. On estime qu'environ 40'000 personnes sont à ce jour porteuses du virus en Suisse. Malgré la disponibilité de médicaments efficaces et sûrs, nombreuses barrières s'opposent à ce que tous les patients puissent en bénéficier: manque de prise de conscience au niveau de la population infectée, politiques de dépistage inadéquates, prix des médicaments. En outres, ils subsistent des questions concernant la morbidité résiduelle chez les patients guéris après traitement: risque de cancer du foie pas complètement disparu et persistance de certaines manifestations extra-hépatiques, notamment métaboliques et immunologiques. L'Etude Suisse de Cohorte Hépatite C, lancée en 2000, a déjà enrôlé plus que 5'400 patients infecté par ce virus. Les patients sont répertoriés et suivis auprès de 8 centres hospitaliers suisses. La collecte annuelle de données cliniques et d'échantillons biologiques dans le contexte de cette étude longitudinale permet aux investigateurs suisses et étrangers de mener des études pour répondre aux nombreuses questions ouvertes dans le domaine de l'hépatite C.
Direct link to Lay Summary Last update: 13.11.2017

Responsible applicant and co-applicants

Employees

Project partner

Publications

Publication
Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents
Terziroli Beretta-Piccoli Benedetta, Di Bartolomeo Claudia, Deleonardi Gaia, Grondona Ana Gabriela, Silvestri Tania, Tesei Cinzia, Melidona Laura, Cerny Andreas, Mertens Joachim, Semmo Nasser, Semela David, Moradpour Darius, Mieli-Vergani Giorgina, Vergani Diego, Muratori Luigi (2019), Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents, in Journal of Autoimmunity, 102, 89-95.
Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study
Brezzi Matteo, Bertisch Barbara, Roelens Maroussia, Moradpour Darius, Terziroli Beretta-Piccoli Benedetta, Semmo Nasser, Müllhaupt Beat, Semela David, Negro Francesco, Keiser Olivia (2019), Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study, in PLOS ONE, 14(6), e0218706-e0218706.
Very Low Hepatitis C Viral Loads in Treatment-naive Persons: Do They Compromise Hepatitis C Virus Antigen Testing?
Bertisch Barbara, Brezzi Matteo, Negro Francesco, Müllhaupt Beat, Ottiger Cornelia, Künzler-Heule Patrizia, Schmid Patrick, Giudici Fabio, Clerc Olivier, Moriggia Alberto, Roelens Maroussia, Marinucci Francesco, Zehnder Cinzia, Moradpour Darius, Keiser Olivia, Negro Francesco, Kaiser Laurent, Heim Markus, Hirsch Hans, Dufour Jean-François, Semmo Nasser, Moradpour Darius, Aubert Vincent, Siegrist Hans H, et al. (2019), Very Low Hepatitis C Viral Loads in Treatment-naive Persons: Do They Compromise Hepatitis C Virus Antigen Testing?, in Clinical Infectious Diseases, 653.
Trends in hepatitis C-related mortality in Switzerland
Keiser O., Giudici F., Müllhaupt B., Junker C., Dufour J. -F., Moradpour D., Bruggmann P., Terziroli B., Semela D., Brezzi M., Bertisch B., Estill J., Negro F., Spoerri A. (2018), Trends in hepatitis C-related mortality in Switzerland, in Journal of Viral Hepatitis, 25(2), 152-160.
Identification of an endoglin variant associated with HCV-related liver fibrosis pro-gression by next-generation sequencing
About Frédégonde, BibertStéphanie, JuanguyEmmanuelle, NalpasBertrand, LorenzoLazaro, RattinaVimel, ZarhrateMohammed, HaneinSylvain, MunteanuMona, MüllhauptBeat, SemelaDavid, SemmoNasser, CasanovaJean-Laurent, TheodorouIoannis, SultanikPhilippe, PoynardThierry, PolStanislas, BochudPierre-Yves, CobatAurélie, Aebl Laurent, Identification of an endoglin variant associated with HCV-related liver fibrosis pro-gression by next-generation sequencing, in Front Genet, 10, 1024.

Collaboration

Group / person Country
Types of collaboration
French ANRS HC EP 26 Genoscan Study Group France (Europe)
- in-depth/constructive exchanges on approaches, methods or results
- Publication

Associated projects

Number Title Start Funding scheme
166609 Hepatitis C virus and glucose and lipid metabolism: molecular interactions and significance 01.04.2016 Project funding (special)
148417 The Swiss Hepatitis C Cohort Study 01.01.2014 Cohort Studies Large
146143 Understanding and Predicting the Hepatitis C Epidemic in HIV-infected Patients 01.05.2013 Project funding (special)

Abstract

The hepatitis C virus (HCV) is a major human pathogen, affecting approximately 71 million persons globally, and ~60,000 in Switzerland. Hepatitis C is an important cause of liver- and non-liver-related morbidity and mortality. Hepatitis C is not only the first indication to liver transplant in most Western countries, but, even in the precirrhotic stage, it also exerts a significant decrease in quality-of-life in a large proportion of patients. Incidence and prevalence data suggest that impressive increases in advanced liver diseases states and complications in Switzerland will occur during the next 10 years, translating into a dramatic increase in HCV-related health care costs. Available therapies are safe end effective, allow curing HCV infection in >95% of patients. However, barriers to therapy are and will remain significant, due to ineffective screening strategies, insufficient retention in care, and high costs. In addition, morbidity after cure may remain significant, especially as far as hepatocellular carcinoma recurrence is concerned. Thus, HCV infection impacts heavily today and will continue to impact in the mid-term future on patients' quality of life and health care resources. Large population-based studies have been proven to be the most meaningful approach to verify working hypotheses on clinical and pathogenetic issues regarding HCV infection. The Swiss Hepatitis C Cohort Study (SCCS) was founded in 2000 by representatives of the 8 major HCV tertiary referral centers across Switzerland. The SCCS has continued to recruit patients during the past 12 years, despite severe budgetary restrictions, and can count today on >5,200 anti-HCV+ enrolled patients, representative of the general HCV-infected population. Data and samples collected within the framework of the SCCS have helped accomplishing several seminal scientific projects, including the pioneering characterization of the clinical significance of IFNL3 gene polymorphisms. In the next years, the SCCS will provide a very powerful framework for generating additional information on the pathogenesis and natural history of HCV infection, and for contributing efficacy and safety data of novel antiviral therapies.
-